.Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H05A_ParathyroidHormonesAndAnalogues.H05AA05_Palopegteriparatide.Palopegteriparatide .Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H05A_ParathyroidHormonesAndAnalogues.H05AA05_Palopegteriparatide.Palopegteriparatide| name: | Palopegteriparatide | |
| ATC code: | H05AA05 | |
| route: | subcutaneous | |
| compartments: | 1 | |
| dosage: | 80 | mg |
| volume of distribution: | 4 | L |
| clearance: | 0.25 | L/h |
| other parameters in model implementation | ||
Palopegteriparatide is a long-acting parathyroid hormone (PTH) analog developed for the treatment of chronic hypoparathyroidism. It is a pegylated form of the PTH (1-34) fragment, designed to provide sustained exposure and physiological calcium regulation. As of 2024, it is not widely approved for clinical use but has been investigated in clinical trials.
No published clinical pharmacokinetic studies are available for palopegteriparatide in humans as of 2024. The following parameters are estimated based on its classification as a pegylated PTH analog intended for subcutaneous dosing.